drugset / Trial / NCT05515289
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 24-30 subjects. Subjects will take the SHR6390 on Day1.
Timeline
- Start
- 2022-12-18
- Primary completion
- 2023-08-28
- Completion
- 2023-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | — | — |